CIK 0001710072 · Large accelerated filer
Edgewise Therapeutics, Inc.
Sign in to watch- Ticker
- EWTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 821725586
- Phone
- 720-262-7002
- Business address
- 1715 38TH ST, BOULDER, CO, 80301
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $201,787
- in 1 filing
Net −$201,787. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-28 | Donovan Joanne M. CMO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −25,000 | 175,000 | ||
| 2025-01-21 | Blaustein Robert Chief Development Officer | Grant or award · Restricted Stock Units | +30,000 | 30,000 | ||
| 2025-01-21 | Blaustein Robert Chief Development Officer | Grant or award · Stock Options (Right to buy) | +160,000 | 160,000 | ||
| 2024-12-30 | Russell Alan J Chief Scientific Officer | Option exercise 10b5-1 | +100,000 | $0.18 | $18K | 114,863 |
| 2024-12-30 | Russell Alan J Chief Scientific Officer | Sale 10b5-1 | −100,000 | $27.37 | $2.7M | 14,863 |
| 2024-12-30 | Russell Alan J Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −100,000 | 1,356,780 | ||
| 2024-12-24 | Semigran Marc Chief Development Officer | Option exercise 10b5-1 | +29,709 | $8.94 | $266K | 36,425 |
| 2024-12-24 | Semigran Marc Chief Development Officer | Sale 10b5-1 | −27,980 | $29.66 | $830K | 8,445 |
| 2024-12-24 | Semigran Marc Chief Development Officer | Sale 10b5-1 | −1,729 | $30.08 | $52K | 6,716 |
| 2024-12-24 | Semigran Marc Chief Development Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −29,709 | 270,291 | ||
| 2024-10-11 | Carruthers R Michael Chief Financial Officer | Option exercise | +70,000 | $0.71 | $50K | 76,904 |
| 2024-10-11 | Carruthers R Michael Chief Financial Officer | Option exercise · Stock Option (Right to Buy) | −70,000 | 127,122 | ||
| 2024-09-23 | MOORE JOHN R General Counsel | Option exercise | +20,922 | $0.71 | $15K | 24,174 |
| 2024-09-23 | MOORE JOHN R General Counsel | Sale | −20,922 | $27.63 | $578K | 3,252 |
| 2024-09-23 | MOORE JOHN R General Counsel | Option exercise · Stock Option (Right to Buy) | −20,922 | 41,636 | ||
| 2024-09-20 | Russell Alan J Chief Scientific Officer | Option exercise | +75,000 | $0.18 | $14K | 87,719 |
| 2024-09-20 | Russell Alan J Chief Scientific Officer | Sale | −74,185 | $28.25 | $2.1M | 13,534 |
| 2024-09-20 | Russell Alan J Chief Scientific Officer | Sale | −815 | $29.51 | $24K | 12,719 |
| 2024-09-20 | Russell Alan J Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) | −75,000 | 1,456,780 | ||
| 2024-09-20 | MOORE JOHN R General Counsel | Option exercise | +50,000 | $0.71 | $36K | 53,252 |
Page 11 of 26 · 509 trades